Zoetis Stock Price and Value Analysis

Zoetis (NYSE:ZTS) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Zoetis to reach your target.

Target type

ZTS Free Cash Flow Trend

Free Cash Flow trendline for ZTS
Free Cash Flow trendline for Zoetis
CSV

Based on historical returns, we believe that Zoetis can grow its free cash at a rate of about 10%. That's positive!

AdvantagesDisadvantages
  • This company has stable growth.
  • This company is making money at a great rate!
  • This company has a high dividend yield.
  • This stock looks overpriced.
  • This company is less known than others.

Inside the ZTS Numbers

ZTS Price
(Zoetis stock price per share)
$79.11
[?] ZTS Fair Price
(based on intrinsic value)
$8.20
[?] ZTS Safety Price (based on a variable margin of safety) $4.92
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 33% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 18%
[?] Dividend Yield 2.59% (tax impact)
Shares Shorted 16,722,420

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 16,722,420 shares shorted. With 405,479,136 shares available for purchase and an average trading volume over the past 10 trading days of 4,596,430, it would take at least 3.6 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2011 1555280 362
2012 1555280 324
2013 1555280 533
2014 1555280 470
2015 1555280 494
2016 1555280 527
2017 1555280 1,140
2018 1555280 1,554
2019 1555280 1,503
2020 1555280 1,788
2021 1555280 1,823
2022 1555280 1,449
2023 1555280 1,811
2024 1555280 2,372
2025 1555280 2,290

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 15 fiscal years from 2011 to 2025 with positive net income, operating cash flow totaled $23,027 million against net income of $20,012 million, or 1.15 times.

In 2025, operating cash flow was 1.09 times net income, compared with 1.38 times for the earliest three years (2011 to 2013).

In 2025, capital expenditures were $621 million, 21.4% of operating cash flow of $2,904 million, which leaves an estimated $2,283 million after capex. Across the 15 years with reported capex, it averaged 24.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 1.09, at least 0.25 under the 1.38 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2011 245 497 135 2.03
2012 436 454 126 1.04
2013 504 681 184 1.35
2014 583 626 180 1.07
2015 339 664 224 1.96
2016 821 713 216 0.87
2017 864 1,346 224 1.56
2018 1,428 1,790 338 1.25
2019 1,500 1,795 460 1.20
2020 1,638 2,126 453 1.30
2021 2,037 2,213 477 1.09
2022 2,114 1,912 586 0.90
2023 2,344 2,353 732 1.00
2024 2,486 2,953 655 1.19
2025 2,673 2,904 621 1.09

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $16,257 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $4,783 million, 29.4% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $7,909 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $1,137 million, 49.7% of estimated free cash flow of $2,290 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 527 188 300 488 92.6%
2017 1,140 206 500 706 61.9%
2018 1,554 243 698 941 60.6%
2019 1,503 314 626 940 62.6%
2020 1,788 380 250 630 35.2%
2021 1,823 474 743 1,217 66.8%
2022 1,449 611 1,594 2,205 152.2%
2023 1,811 692 1,092 1,784 98.5%
2024 2,372 786 1,858 2,644 111.4%
2025 2,290 889 248 1,137 49.7%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $4,233 million in 2011 and $9,467 million in 2025, a compound annual growth rate of 5.9% over 14 years.

Revenue rose 2.3% from 2024 to 2025.

Our estimated free cash flow was $2,290 million in 2025, 24.2% of revenue. In 2011 the estimated margin was 8.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2011 4,233 362 8.6%
2012 4,336 324 7.5%
2013 4,561 533 11.7%
2014 4,785 470 9.8%
2015 4,765 494 10.4%
2016 4,888 527 10.8%
2017 5,307 1,140 21.5%
2018 5,825 1,554 26.7%
2019 6,260 1,503 24.0%
2020 6,675 1,788 26.8%
2021 7,776 1,823 23.4%
2022 8,080 1,449 17.9%
2023 8,544 1,811 21.2%
2024 9,256 2,372 25.6%
2025 9,467 2,290 24.2%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $2,312 million against total liabilities of $12,136 million, or 19.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 78.5% of total assets in 2025, compared with 35.5% in 2012, an increase of 43.0 percentage points.

Stockholders equity was $3,331 million in 2025, compared with $4,041 million in 2012, a fall of 17.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 21.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2012 6,262 317 2,221 4,041
2013 6,558 610 5,596 962
2014 6,588 882 5,251 1,337
2015 7,913 1,154 6,822 1,091
2016 7,649 727 6,150 1,499
2017 8,586 1,564 6,800 1,786
2018 10,777 1,602 8,592 2,185
2019 11,545 1,934 8,837 2,708
2020 13,609 3,604 9,836 3,773
2021 13,900 3,485 9,356 4,544
2022 14,925 3,581 10,522 4,403
2023 14,286 2,041 9,295 4,991
2024 14,237 1,987 9,467 4,770
2025 15,467 2,312 12,136 3,331

Price Versus Our Estimated Value

Every one of the 15 fiscal years we have for Zoetis under its current filer shows positive free cash flow.

Free cash flow from the first three years of data averaged $406 million, and from the last three $2,158 million: a sharp rise.

Year-to-year variability in free cash flow is fairly steady, measured at 18%.

At $79.11, the price is above our fair value estimate of $8.20 for Zoetis.

The dividend yield for Zoetis is 2.59%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 33% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Zoetis, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above
Viatris (VTRS) 22,505 - 2.4% - 2% below
Teva Pharmaceutical Industries Limited (TEVA) 44,970 89.6 - 13.5% 47% below
Jazz Pharmaceuticals plc (JAZZ) 14,780 68.1 - 3.4% 53% below
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1555280.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ZTS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ZTS

Does Zoetis have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ZTS

This example shows how we apply the Trendshare checklist to ZTS: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 79.11
    • Market cap: $32B
    • EPS: 5.88
  2. Step 2 — Valuation checks

    • P/E: 13.454
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.